Policy & Regulation
Paragon unveils new coronavirus-related CleanPlex NGS tests along with new CleanPlex ACE2 & TMPRSS2 Panel
15 October 2020 -

Precision medicine company Paragon Genomics Inc reported on Wednesday the launch of new coronavirus-related CleanPlex NGS tests with the new CleanPlex ACE2 & TMPRSS2 Panel, a multiplex PCR-based targeted sequencing assay that assesses key human genetic factors affecting patient susceptibility to COVID-19 infection and the likely severity of illness.

The company added the new CleanPlex SARS-CoV-2 FLEX Research Panel provides accurate mutation detection and genome coverage as the SARS-CoV-2 virus continues to mutate. The new panels allows sequencing of the entire SARS-CoV-2 genome and enables researchers to obtain accurate nucleic acid-level information on the virus for strain-typing, mutation monitoring and other epidemiological studies.

According to the company, the CleanPlex ACE2 & TMPRSS2 Panel focuses on identifying genetic mutations in patients that are related to SARS-CoV-2 disease susceptibility and severity. It targets genes affecting the binding affinity and expression of angiotensin-converting enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2), which play critical roles in helping the virus enter into patients' cells.

Next week, the company will release an early access edition of the CleanPlex Respiratory Research Panel combining assays for SARS-CoV-2, influenza A subtypes H1N1, H1N2, H3N2 and influenza B. as well as the new CleanPlex Plated Unique Dual-Indexed PCR Primers for Illumina sequencing of CleanPlex SARS-CoV-2 NGS panels to run up to 3072 CleanPlex sequencing samples simultaneously.



Related Headlines